Syros Pharmaceuticals Inc (SYRS)

NASDAQ
2.260
-0.070(-3.00%)
  • Volume:
    5,932
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    2.250 - 2.260

SYRS Overview

Prev. Close
2.33
Day's Range
2.25-2.26
Revenue
21.39M
Open
2.25
52 wk Range
2.06-13.42
EPS
-1.62
Volume
5,932
Market Cap
144.34M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
351,590
P/E Ratio
-
Beta
1.89
1-Year Change
-80.89%
Shares Outstanding
61,947,150
Next Earnings Date
09 Mar 2022
What is your sentiment on Syros Pharmaceuticals Inc?
or
Vote to see community's results!

Syros Pharmaceuticals Inc Company Profile

Employees
103

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicine. Its lead product candidates include SY-1425, SY-2101 and SY-5609. Its SY-1425, is a selective retinoic acid receptor alpha (RARα) that is being evaluated in combination with azacytidine used to treat acute myeloid leukemia (AML). Its SY-2101, a novel oral form of arsenic trioxide (ATO) being developed for the treatment of AML. Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.